AU
UK
CA
NZ
IND
US
Sanofi (NASDAQ: SNY)is a global healthcare company focused on developing medicines and vaccines, with an emphasis on innovation, sustainability, and social responsibility. They company has announced a definitive agreement to acquireVigil Neuroscience, Inc. (NASDAQ: VIGL), a clinical-stage biotechnology company focused on treatments for neurodegenerative …
Polyrizon Ltd. (Nasdaq: PLRZ), a biotech firm focused on intranasal hydrogel technologies, has released findings from recent ex vivo studies demonstrating key performance characteristics of its proprietary formulation. The tests focused on two critical aspects: surface coverage and mucoadhesion—both fundamental to the platform’s intended …
Weave (NYSE: WEAV)has completed its acquisition of TrueLark, an AI-based front-desk automation and receptionist platform, advancing its broader strategy of integrating artificial intelligence into healthcare communications. The deal represents a step forward in Weave’s focus on expanding its offerings for small and medium-sized healthcare …
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW), a company specializing in the development and commercialization of medicines targeting infectious diseases, announced its financial results for the first quarter ended March 31, 2025. The results highlighted continued revenue growth and product traction, particularly in the …
CureVac N.V. (NASDAQ: CVAC), a global biopharmaceutical leader in messenger RNA (mRNA) innovation, has secured another key legal victory in its ongoing patent litigation against BioNTech SE. The European Patent Office (EPO) has upheld the validity of CureVac’s European patent EP 4 023 755 …
AbCellera Biologics Inc. (Nasdaq: ABCL) has received a No Objection Letter (NOL) from Health Canada, authorizing the company to proceed with a Phase 1 clinical trial for its investigational drug candidate ABCL635. The study is focused on addressing moderate-to-severe vasomotor symptoms (VMS), commonly referred …
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company focused on treating Obstructive Sleep Apnea (OSA), announced its financial results for the first quarter of 2025, reporting revenue of €1.1 million, down from €1.2 million in the same quarter last year.
Highlights
argenx SE [Euronext & Nasdaq: ARGX], a biotechnology firm focused on autoimmune diseases, announced its financial results for the first quarter of 2025, alongside updates on its expanding pipeline and regulatory progress. The company reported $790 million in global net product sales from VYVGART® …
Evotec SE (NASDAQ: EVO) has reported its financial results for Q1 2025, showcasing a solid start to the year despite challenges in the drug discovery market. The company achieved revenues of €200 million, a 4% decline compared to Q1 2024, aligning with their expectations. …
Please wait processing your request...